Author

S. McQuaid

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

V. Bingham· 2 shared A. Gilmore· 1 shared A. M. McCorry· 1 shared C. Graham· 1 shared C. Holohan· 1 shared D. B. Longley· 1 shared D. G. McArt· 1 shared D. Griffin· 1 shared

Activity by Year

2017-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

V. Bingham

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer

E. E. Parkes, M. P. Humphries, E. Gilmore, F. A. Sidi, V. Bingham, S. M. Phyu, S. G. Craig, C. Graham, J. Miller, D. Griffin, R. D. Kennedy, S. F. Bakhoum, S. McQuaid, M. Salto-Tellez, N. E. Buckley

The paper identifies perinuclear STING (pnSTING) in ER+ breast cancer as a prognostic marker linked to immune infiltration and poor outcomes in low pnSTING tumors.

bioRxiv · Jul 23, 2020Cancer Biology

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

P. D. Dunne, H. G. Coleman, P. Bankhead, M. Alderdice, R. T. Gray, S. McQuaid, V. Bingham, M. B. Loughrey, J. A. James, A. M. McCorry, A. Gilmore, C. Holohan, D. Klingbiel, S. Tejpar, P. G. Johnston, , M. Lawler

The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.

bioRxiv · Oct 23, 2017Cancer Biology